Skip to content
Article Rich – Lifestyle
Author:
Nutshell Therapeutics (Shanghai) Co., Ltd.
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics’ NTS231 Received FDA IND Clearance
September 25, 2026